15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Bioventus Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $14.00 to $19.00, so the covering firms are broadly aligned. The average target of $16.00 sits 16% above the current $13.85. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.25 next quarter toward $0.92 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Bioventus Inc.
As of Sep, 4 of 4 firms rate BVS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BVS EPS & revenue forecast
EPS · NEXT QUARTER
$0.25
Range $0.23 – $0.28 · 5 analysts · +4% YoY
Next period, 5 analysts expect Bioventus Inc to earn $0.25 a share (range $0.23 – $0.28), versus $0.24 a year earlier. Full-year consensus is $0.78, growing to $0.92 the year after.
REVENUE · NEXT QUARTER
$170.0M
Range $168.4M – $170.8M · 5 analysts · +8% YoY
Revenue is expected to reach $170.0M (range $168.4M – $170.8M), +7.6% year-over-year. Full-year consensus is $604.8M, rising to $645.6M next year.
Top analysts covering Bioventus Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BVS.
#1
Ross Osborn
Cantor Fitzgerald · Rank #166
Buy
$14.00+1.1% to target
Overall win rate
33%
+ Follow
#2
CC
Caitlin Cronin
Canaccord Genuity · Rank #192
Buy
$19.00+37.2% to target
Overall win rate
40%
+ Follow
#3
William Plovanic
Canaccord Genuity · Rank #243
Buy
$15.00+8.3% to target
Overall win rate
37%
+ Follow
#4
Michael Petusky
Barrington Research · Rank #373
Buy
$14.00+1.1% to target
Overall win rate
31%
+ Follow
#5
AN
Alexander Nowak
Craig-Hallum
Buy
$16.00+15.5% to target
Coverage
—
+ Follow
BVS stock forecast FAQ
What is BVS's average 12-month price target?+
The 4 analysts with a live target average $16.00 for Bioventus Inc over the next 12 months, ranging from a $19.00 high to a $14.00 low.
Is BVS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BVS?+
The Street-high target is $19.00 (Canaccord Genuity), and the Street-low is $14.00 (Barrington Research). The average of all 4 active targets is $16.00.
How many Wall Street analysts cover BVS?+
4 analysts have an active rating on Bioventus Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering BVS?+
Among analysts who currently cover BVS, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #166). Their current call is Buy with a $14.00 target.
What is Bioventus Inc's projected EPS for next quarter?+
The consensus estimate is $0.25 per share (range $0.23 – $0.28) across 5 analysts. Full-year EPS is projected at $0.78, rising to $0.92 the following year.
How much revenue is Bioventus Inc expected to report next quarter?+
Consensus revenue is $170.0M (range $168.4M – $170.8M). Full-year revenue is projected at $604.8M, growing to $645.6M next year.
Have analysts been upgrading or downgrading BVS lately?+
As of Sep, 4 of 4 firms rate BVS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BVS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
